Blog >


Umbrex is pleased to welcome Zachary Hoyt with Zelwin Enterprises. Zack is a former McKinsey consultant within the Private Equity and Principal Investors practice. He has extensive experience with strategy work, commercial due diligence, and portfolio company value creation across a range of industries including tech, financial services, government contracting (both federal and state) and […]

Umbrex is pleased to welcome Tom Goldenberg with Goldenberg Solutions. Tom is a technology expert with experience building successful new ventures. A former startup CTO and co-founder, at BCG he helped strategize a new digital business that surpassed $1 billion valuation. At McKinsey, he led teams of data scientists to implement AI solutions for clients […]

Umbrex is pleased to welcome Danish Dhanani. Danish is a seasoned strategy manager who loves launching / scaling new tech products that enable sustainable revenue growth and address big Climate & Social Impact challenges. Danish has spearheaded initiatives for 15+ major corporate clients, mainly focused on growing new business ventures across sectors — e.g., B2B […]

In this article, Suhail Acharya makes a case for a high-quality primary care network to help optimize hospital capacity. Recent trends appear to make a case for health systems needing to diversify their revenue to maintain financial health. However, one strategy that is underappreciated is investing in primary care to optimize hospital capacity and generate […]

Michelle Zimmerman shares an article on what you may not know about insurance providers and healthcare. We all know that provider networks matter in healthcare. We understand that insurance products with both in-network and out-of-network coverage are more expensive and that if we want to keep our existing providers we should carefully check whether each […]

Umbrex is pleased to welcome Sumin Koo with BioMed Resolve.  Sumin began her career in McKinsey & Co’s healthcare practice. She served pharma and biotech clients, focused on Merger & Acquisitions and R&D strategy / operations. Post-McKinsey, she joined Novartis to run late-stage clinical trials and shepherded assets through to obtain FDA License approvals. She […]

Umbrex is pleased to welcome Jon Paul Watts with Halite Group. Jon has nearly 25 years of operations and technology consulting experience working with top financial services, healthcare, consumer products, defense, mining and technology companies. He has significant expertise in helping clients develop business models, build actionable transformation strategies, design digital first operating models and […]

Umbrex is pleased to welcome Michelle Zimmerman.  Michelle is a C-Level Healthcare Executive with extensive experience building and scaling public and private companies in precision medicine, digital health, health services, and health insurance. Built and led cross-functional teams of 100+ across sales, operations, clinical, product, and business development. Expertise in value-based payments, population health, genetics, real-world evidence (RWE) & […]

Umbrex is pleased to welcome Matthias Burger. Starting his career in 2001, Matthias Burger spent seven years as a strategy consultant at Monitor Group, developing and implementing corporate, growth, and go-to-market strategies mostly for Healthcare clients, bevor venturing out as an independent consultant. From 2012 to 2016 he worked exclusively for mid-cap PE Fund Monitor […]

In this post, Uwe Heiss explores the effect of placebo pricing on pain management. Here is an interesting study about placebo pricing (Waber 2008). Dan Ariely, a behavioral economist at Duke University showed in a study with 82 healthy volunteers that the price of pills contributes to their placebo effect. All study participants got a […]